SCHEMBL21533461

SCHEMBL21533461

Cc1cc(N2CCN(C(=O)Nc3ncc(Cl)s3)CC2)ccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.52
TP53 P04637 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
POLB P06746 1/20 0.52
CCR2 P41597 1/20 0.48
PANK3 Q9H999 1/20 0.47
ALDH1A1 P00352 1/20 0.44
GFER P55789 1/20 0.44
CA2 P00918 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA9 Q16790 1/20 0.43
CCR1 P32246 1/20 0.43
MAPK1 P28482 2/20 0.43
NOD2 Q9HC29 1/20 0.43
HTT P42858 1/20 0.42
CHEK1 O14757 1/20 0.42
OGA O60502 1/20 0.42
ALK Q9UM73 1/20 0.41
STS P08842 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21533536 0.92 MAPT (0.53) MAPTTP53SMN1; SMN2POLBCCR2
SCHEMBL21533597 0.91 MAPT (0.52) MAPTTP53SMN1; SMN2POLBPANK3
SCHEMBL21533596 0.90 MAPT (0.58) MAPTTP53SMN1; SMN2POLBCCR2
SCHEMBL21533462 0.89 MAPT (0.55) MAPTTP53SMN1; SMN2POLBCCR2
SCHEMBL21533627 0.87 KDR (0.51) MAPTTP53SMN1; SMN2POLBPANK3
SCHEMBL21533587 0.86 MAPT (0.54) MAPTTP53SMN1; SMN2POLBCCR2
SCHEMBL21533586 0.83 MAPT (0.61) MAPTTP53SMN1; SMN2POLBPANK3
SCHEMBL21533593 0.83 MAPT (0.53) MAPTTP53SMN1; SMN2POLBPANK3
SCHEMBL21533457 0.79 KDR (0.49) MAPTTP53SMN1; SMN2POLBPANK3
SCHEMBL21533540 0.77 RAB9A (0.57) MAPTTP53SMN1; SMN2PANK3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190330167-A1 ACTIVATORS OF HIV LATENCY THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2019-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190330167-A1 ACTIVATORS OF HIV LATENCY NFATC1, EP300, CD69 MAPT 2314/4885TP53 3351/4885SMN1; SMN2 4829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.